vs
汉瑞祥（HSIC）与美盛公司（MOS）财务数据对比。点击上方公司名可切换其他公司
汉瑞祥的季度营收约是美盛公司的1.2倍（$3.4B vs $3.0B），汉瑞祥净利率更高（2.9% vs -17.5%，领先20.4%），汉瑞祥同比增速更快（7.7% vs 5.6%），汉瑞祥自由现金流更多（$338.0M vs $-405.7M），过去两年美盛公司的营收复合增速更高（5.3% vs 4.1%）
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
美盛公司（The Mosaic Company）是总部位于美国佛罗里达州坦帕的化工企业，主营磷矿、钾矿开采及尿素采集，依托多元国际分销网络和旗下肥料业务板块生产销售农用肥料，是美国规模最大的钾肥、磷肥生产商。
HSIC vs MOS — 直观对比
营收规模更大
HSIC
是对方的1.2倍
$3.0B
营收增速更快
HSIC
高出2.1%
5.6%
净利率更高
HSIC
高出20.4%
-17.5%
自由现金流更多
HSIC
多$743.7M
$-405.7M
两年增速更快
MOS
近两年复合增速
4.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.4B | $3.0B |
| 净利润 | $101.0M | $-519.5M |
| 毛利率 | 30.9% | 11.5% |
| 营业利润率 | 4.7% | -3.4% |
| 净利率 | 2.9% | -17.5% |
| 营收同比 | 7.7% | 5.6% |
| 净利润同比 | 7.4% | -407.4% |
| 每股收益（稀释后） | $0.85 | $-1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HSICMOS
| Q4 25 | $3.4B | $3.0B | ||
| Q3 25 | $3.3B | $3.5B | ||
| Q2 25 | $3.2B | $3.0B | ||
| Q1 25 | $3.2B | $2.6B | ||
| Q4 24 | $3.2B | $2.8B | ||
| Q3 24 | $3.2B | $2.8B | ||
| Q2 24 | $3.1B | $2.8B | ||
| Q1 24 | $3.2B | $2.7B |
净利润HSICMOS
| Q4 25 | $101.0M | $-519.5M | ||
| Q3 25 | $101.0M | $411.4M | ||
| Q2 25 | $86.0M | $410.7M | ||
| Q1 25 | $110.0M | $238.1M | ||
| Q4 24 | $94.0M | $169.0M | ||
| Q3 24 | $99.0M | $122.2M | ||
| Q2 24 | $104.0M | $-161.5M | ||
| Q1 24 | $93.0M | $45.2M |
毛利率HSICMOS
| Q4 25 | 30.9% | 11.5% | ||
| Q3 25 | 30.7% | 16.0% | ||
| Q2 25 | 31.4% | 17.3% | ||
| Q1 25 | 31.6% | 18.6% | ||
| Q4 24 | 31.1% | 10.7% | ||
| Q3 24 | 31.3% | 14.8% | ||
| Q2 24 | 32.5% | 14.0% | ||
| Q1 24 | 31.9% | 14.9% |
营业利润率HSICMOS
| Q4 25 | 4.7% | -3.4% | ||
| Q3 25 | 4.9% | 9.8% | ||
| Q2 25 | 4.7% | 8.1% | ||
| Q1 25 | 5.5% | 12.9% | ||
| Q4 24 | 4.9% | 3.5% | ||
| Q3 24 | 4.9% | 4.1% | ||
| Q2 24 | 5.1% | 8.3% | ||
| Q1 24 | 4.7% | 6.5% |
净利率HSICMOS
| Q4 25 | 2.9% | -17.5% | ||
| Q3 25 | 3.0% | 11.9% | ||
| Q2 25 | 2.7% | 13.7% | ||
| Q1 25 | 3.5% | 9.1% | ||
| Q4 24 | 2.9% | 6.0% | ||
| Q3 24 | 3.1% | 4.3% | ||
| Q2 24 | 3.3% | -5.7% | ||
| Q1 24 | 2.9% | 1.7% |
每股收益（稀释后）HSICMOS
| Q4 25 | $0.85 | $-1.63 | ||
| Q3 25 | $0.84 | $1.29 | ||
| Q2 25 | $0.70 | $1.29 | ||
| Q1 25 | $0.88 | $0.75 | ||
| Q4 24 | $0.75 | $0.53 | ||
| Q3 24 | $0.78 | $0.38 | ||
| Q2 24 | $0.80 | $-0.50 | ||
| Q1 24 | $0.72 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $156.0M | $276.6M |
| 总债务越低越好 | $2.3B | $4.3B |
| 股东权益账面价值 | $3.2B | $12.1B |
| 总资产 | $11.2B | $24.5B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资HSICMOS
| Q4 25 | $156.0M | $276.6M | ||
| Q3 25 | $136.0M | $153.3M | ||
| Q2 25 | $145.0M | $286.2M | ||
| Q1 25 | $127.0M | $259.2M | ||
| Q4 24 | $122.0M | $272.8M | ||
| Q3 24 | $126.0M | $301.6M | ||
| Q2 24 | $138.0M | $322.0M | ||
| Q1 24 | $159.0M | $336.7M |
总债务HSICMOS
| Q4 25 | $2.3B | $4.3B | ||
| Q3 25 | $2.2B | $3.4B | ||
| Q2 25 | $2.1B | $3.3B | ||
| Q1 25 | $2.0B | $3.3B | ||
| Q4 24 | $1.8B | $3.3B | ||
| Q3 24 | $1.9B | $3.2B | ||
| Q2 24 | $1.9B | $3.2B | ||
| Q1 24 | $2.0B | $3.2B |
股东权益HSICMOS
| Q4 25 | $3.2B | $12.1B | ||
| Q3 25 | $3.4B | $12.8B | ||
| Q2 25 | $3.4B | $12.4B | ||
| Q1 25 | $3.3B | $11.8B | ||
| Q4 24 | $3.4B | $11.5B | ||
| Q3 24 | $3.5B | $11.8B | ||
| Q2 24 | $3.5B | $11.7B | ||
| Q1 24 | $3.6B | $12.0B |
总资产HSICMOS
| Q4 25 | $11.2B | $24.5B | ||
| Q3 25 | $11.1B | $24.7B | ||
| Q2 25 | $10.9B | $24.3B | ||
| Q1 25 | $10.5B | $23.2B | ||
| Q4 24 | $10.2B | $22.9B | ||
| Q3 24 | $10.6B | $23.3B | ||
| Q2 24 | $10.3B | $22.6B | ||
| Q1 24 | $10.1B | $22.9B |
负债/权益比HSICMOS
| Q4 25 | 0.71× | 0.35× | ||
| Q3 25 | 0.64× | 0.26× | ||
| Q2 25 | 0.61× | 0.27× | ||
| Q1 25 | 0.59× | 0.28× | ||
| Q4 24 | 0.54× | 0.29× | ||
| Q3 24 | 0.54× | 0.27× | ||
| Q2 24 | 0.54× | 0.27× | ||
| Q1 24 | 0.56× | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $381.0M | $-56.1M |
| 自由现金流经营现金流 - 资本支出 | $338.0M | $-405.7M |
| 自由现金流率自由现金流/营收 | 9.8% | -13.6% |
| 资本支出强度资本支出/营收 | 1.3% | 11.8% |
| 现金转化率经营现金流/净利润 | 3.77× | — |
| 过去12个月自由现金流最近4个季度 | $573.0M | $-534.6M |
8季度趋势，按日历期对齐
经营现金流HSICMOS
| Q4 25 | $381.0M | $-56.1M | ||
| Q3 25 | $174.0M | $228.5M | ||
| Q2 25 | $120.0M | $609.5M | ||
| Q1 25 | $37.0M | $42.9M | ||
| Q4 24 | $204.0M | $219.3M | ||
| Q3 24 | $151.0M | $312.9M | ||
| Q2 24 | $296.0M | $847.0M | ||
| Q1 24 | $197.0M | $-80.0M |
自由现金流HSICMOS
| Q4 25 | $338.0M | $-405.7M | ||
| Q3 25 | $141.0M | $-135.9M | ||
| Q2 25 | $88.0M | $304.9M | ||
| Q1 25 | $6.0M | $-297.9M | ||
| Q4 24 | $168.0M | $-74.8M | ||
| Q3 24 | $117.0M | $72.1M | ||
| Q2 24 | $259.0M | $513.1M | ||
| Q1 24 | $156.0M | $-463.0M |
自由现金流率HSICMOS
| Q4 25 | 9.8% | -13.6% | ||
| Q3 25 | 4.2% | -3.9% | ||
| Q2 25 | 2.7% | 10.1% | ||
| Q1 25 | 0.2% | -11.4% | ||
| Q4 24 | 5.3% | -2.7% | ||
| Q3 24 | 3.7% | 2.6% | ||
| Q2 24 | 8.3% | 18.2% | ||
| Q1 24 | 4.9% | -17.3% |
资本支出强度HSICMOS
| Q4 25 | 1.3% | 11.8% | ||
| Q3 25 | 1.0% | 10.6% | ||
| Q2 25 | 1.0% | 10.1% | ||
| Q1 25 | 1.0% | 13.0% | ||
| Q4 24 | 1.1% | 10.4% | ||
| Q3 24 | 1.1% | 8.6% | ||
| Q2 24 | 1.2% | 11.9% | ||
| Q1 24 | 1.3% | 14.3% |
现金转化率HSICMOS
| Q4 25 | 3.77× | — | ||
| Q3 25 | 1.72× | 0.56× | ||
| Q2 25 | 1.40× | 1.48× | ||
| Q1 25 | 0.34× | 0.18× | ||
| Q4 24 | 2.17× | 1.30× | ||
| Q3 24 | 1.53× | 2.56× | ||
| Q2 24 | 2.85× | — | ||
| Q1 24 | 2.12× | -1.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
MOS
暂无分部数据
